Panitumumab
As of the edition of 20 October 2026, Panitumumab is an antibody: marketed, first approved in 2006 (US); acts on EGFR; US protection ended in 2018.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2008
- Kind
- Antibody
- Brand name
- Vectibix
- First approved
- 27 September 2006 (US)
- Approvals on record
- 9 in 5 regions
- Holder of the most recent approval
- Amgen; 3 holders in all
- Registered trials
- 225, 42 stopped early
- Disease areas
- Cancer; Digestive system; Lungs and airways; Hormones; Urinary and reproductive; Pregnancy and women's health
US protection
US protection ended in 2018.
US protection ended in 2018, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Amgen. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Panitumumab.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| EGFR | Epidermal growth factor receptor | P00533 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 3 | 1 | 0 |
| Phase 1 | 25 | 11 | 8 | 6 |
| Phase 2 | 168 | 95 | 23 | 32 |
| Phase 3 | 26 | 14 | 7 | 3 |
| Phase 4 | 2 | 0 | 0 | 1 |
| All trials | 225 |